INCB013739 + metformin

INCB013739 + metformin is a combination therapy investigationally evaluated for the treatment of type 2 diabetes mellitus. INCB013739 is an investigational small molecule developed by Incyte, tested as an adjunct to metformin, a well-established oral antihyperglycemic agent. INCB013739 is administered on top of background metformin to assess improvements in glycemic control. Metformin is a biguanide that reduces hepatic glucose production, decreases absorption of glucose in the gut, and increases insulin sensitivity by improving peripheral glucose uptake; it is an established, FDA-approved oral agent for type 2 diabetes. The precise mechanism of action for INCB013739 is not available in public sources, but in this context, the combination was designed to improve glycemic endpoints beyond metformin monotherapy[1][2].